{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T11:34:54Z","timestamp":1766748894224},"reference-count":19,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The pharmacokinetics of intravenous anidulafungin in adult intensive care unit (ICU) patients were assessed in this study and compared with historical data from a general patient population and healthy subjects. Intensive plasma sampling was performed over a dosing interval at steady state from 21 ICU patients with candidemia\/invasive candidiasis. All patients received the recommended dosing regimen (a 200-mg loading dose on day 1, followed by a daily 100-mg maintenance dose), except for a 54-year-old 240-kg female patient (who received a daily 150-mg maintenance dose instead). Plasma samples were assayed for anidulafungin using a validated liquid chromatography-tandem mass spectrometry method. Pharmacokinetic parameters in ICU patients were calculated by a noncompartmental method. With the exclusion of the 240-kg patient, the median (minimum, maximum) age, weight, and body mass index (BMI) of 20 ICU patients were 57 (39, 78) years, 65 (48, 106) kg, and 23.3 (16.2, 33.8) kg\/m\n            <jats:sup>2<\/jats:sup>\n            , respectively. The average anidulafungin area under the curve over the 24-hour dosing interval (AUC\n            <jats:sub>0-24<\/jats:sub>\n            ), maximum concentration (\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            ), and clearance (CL) in 20 ICU patients were 92.7 mg \u00b7 h\/liter, 7.7 mg\/liter, and 1.3 liters\/h, respectively. The exposure in the 240-kg patient at a daily 150-mg dose was within the range observed in ICU patients overall. The average AUC\n            <jats:sub>0-24<\/jats:sub>\n            and\n            <jats:italic>C<\/jats:italic>\n            <jats:sub>max<\/jats:sub>\n            in the general patient population and healthy subjects were 110.3 and 105.9 mg \u00b7 h\/liter and 7.2 and 7.0 mg\/liter, respectively. The pharmacokinetics of anidulafungin in ICU patients appeared to be comparable to those in the general patient population and healthy subjects at the same dosing regimen.\n          <\/jats:p>","DOI":"10.1128\/aac.02139-12","type":"journal-article","created":{"date-parts":[[2013,1,19]],"date-time":"2013-01-19T03:57:28Z","timestamp":1358567848000},"page":"1672-1676","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":58,"title":["Pharmacokinetics of Anidulafungin in Critically Ill Patients with Candidemia\/Invasive Candidiasis"],"prefix":"10.1128","volume":"57","author":[{"given":"Ping","family":"Liu","sequence":"first","affiliation":[{"name":"Clinical Pharmacology, Specialty Care, Pfizer Inc., Groton, Connecticut, USA"}]},{"given":"Markus","family":"Ruhnke","sequence":"additional","affiliation":[{"name":"Department of Medicine, Charit\u00e9 University Hospital, Berlin, Germany"}]},{"given":"Wouter","family":"Meersseman","sequence":"additional","affiliation":[{"name":"Metabolic Diseases-Intensive Care Medicine, University Hospital Leuven, Leuven, Belgium"}]},{"given":"Jos\u00e9 Artur","family":"Paiva","sequence":"additional","affiliation":[{"name":"Department of Emergency and Intensive Care Medicine, Centro Hospitalar S\u00e3o Jo\u00e3o, Porto, Portugal"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[{"name":"Pfizer International Operations, Specialty Care, Paris, France"}]},{"given":"Bharat","family":"Damle","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology, Emerging Markets and Established Products, Pfizer Inc., New York, New York, USA"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1246289"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e318206c1ca"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2006.11.004"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc8117"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc10514"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-008-1338-7"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/596757"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12039"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/2047-783X-16-4-159"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297227"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01279-08"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2012.03784.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-012-6272-4"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm125"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01473-12"},{"key":"e_1_3_2_17_2","volume-title":"Eraxis (anidulafungin) package insert","author":"Pfizer","year":"2010","unstructured":"Pfizer. 2010. Eraxis (anidulafungin) package insert. Pfizer, New York, NY."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006296764"},{"key":"e_1_3_2_19_2","first-page":"465","volume-title":"Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother","author":"Pascual AA","year":"2007","unstructured":"PascualAA SennL BolayS RochatB EggimannP KsontiniR BuclinT BilleJ CalandraT MarchettiO. 2007. Low total plasma concentration of caspofungin in surgical intensive care unit patients, abstr M2025, p 465. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/11318100-000000000-00000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02139-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02139-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:22:40Z","timestamp":1645482160000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02139-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1128\/AAC.02139-12"],"URL":"https:\/\/doi.org\/10.1128\/aac.02139-12","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"2012-10-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}